Nonetheless, NANOG1 and OCT4 levels also consistently increased upon dasatinib and saracatinib treatment in these two HNSCC-derived cell lines (Figure 2D), in good agreement with the previous paper by Koo et al. [33]. This evidence concerns the gene POU5F1 and head and neck squamous cell carcinoma.